JP6951826B2 - ヒト化抗ｃｄ３抗体、その複合体、およびその使用 - Google Patents

ヒト化抗ｃｄ３抗体、その複合体、およびその使用 Download PDF

Info

Publication number
JP6951826B2
JP6951826B2 JP2018539317A JP2018539317A JP6951826B2 JP 6951826 B2 JP6951826 B2 JP 6951826B2 JP 2018539317 A JP2018539317 A JP 2018539317A JP 2018539317 A JP2018539317 A JP 2018539317A JP 6951826 B2 JP6951826 B2 JP 6951826B2
Authority
JP
Japan
Prior art keywords
amino acid
antibody
acid sequence
seq
sequence comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018539317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512002A (ja
JP2019512002A5 (cg-RX-API-DMAC7.html
Inventor
キム，チャンヒョク
ヤング，トラヴィス
キム，ミンスー
マ，ジェニファー
プレスタ，レオナルド
ジー． シュルツ，ピーター
ジー． シュルツ，ピーター
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2019512002A publication Critical patent/JP2019512002A/ja
Publication of JP2019512002A5 publication Critical patent/JP2019512002A5/ja
Priority to JP2021153453A priority Critical patent/JP2022023052A/ja
Application granted granted Critical
Publication of JP6951826B2 publication Critical patent/JP6951826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018539317A 2016-02-04 2017-02-03 ヒト化抗ｃｄ３抗体、その複合体、およびその使用 Active JP6951826B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021153453A JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291143P 2016-02-04 2016-02-04
US62/291,143 2016-02-04
PCT/US2017/016407 WO2017136659A2 (en) 2016-02-04 2017-02-03 Humanized anti-cd3 antibodies, conjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021153453A Division JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Publications (3)

Publication Number Publication Date
JP2019512002A JP2019512002A (ja) 2019-05-09
JP2019512002A5 JP2019512002A5 (cg-RX-API-DMAC7.html) 2020-03-26
JP6951826B2 true JP6951826B2 (ja) 2021-10-20

Family

ID=59501004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018539317A Active JP6951826B2 (ja) 2016-02-04 2017-02-03 ヒト化抗ｃｄ３抗体、その複合体、およびその使用
JP2021153453A Pending JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021153453A Pending JP2022023052A (ja) 2016-02-04 2021-09-21 ヒト化抗ｃｄ３抗体、その複合体、およびその使用

Country Status (9)

Country Link
US (1) US12252534B2 (cg-RX-API-DMAC7.html)
EP (1) EP3411069B1 (cg-RX-API-DMAC7.html)
JP (2) JP6951826B2 (cg-RX-API-DMAC7.html)
KR (1) KR102891788B1 (cg-RX-API-DMAC7.html)
CN (1) CN109069635B (cg-RX-API-DMAC7.html)
AU (1) AU2017213886B2 (cg-RX-API-DMAC7.html)
CA (1) CA3013463C (cg-RX-API-DMAC7.html)
ES (1) ES2992761T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017136659A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970505A4 (en) 2013-03-14 2016-10-19 California Inst Biomedical Res SPECIFIC ANTIBODIES AND USES THEREOF
EP3411069B1 (en) 2016-02-04 2024-07-10 The Scripps Research Institute Humanized anti-cd3 antibodies, conjugates and uses thereof
EP3668898B1 (en) 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
CN111417655A (zh) * 2018-08-28 2020-07-14 润俊(中国)有限公司 抗cd3抗体叶酸生物偶联物及其用途
US20220089722A1 (en) * 2018-12-29 2022-03-24 Nantong Yichen Biopharma. Co. Ltd. Heterodimeric fusion protein
EP3928790A4 (en) * 2019-02-22 2023-01-11 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen binding fragment and application thereof
WO2020232165A1 (en) * 2019-05-14 2020-11-19 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
AU2020359928B2 (en) * 2019-09-30 2025-01-09 Harbour Biomed (Shanghai) Co., Ltd. CD3-targeting antibody, bispecific antibody and use thereof
US20220411530A1 (en) * 2019-11-22 2022-12-29 Nantong Yichen Biopharma. Co. Ltd. PSMA Antibody and Use Thereof
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
TWI827807B (zh) * 2020-02-26 2024-01-01 香港商潤俊（中國）有限公司 抗cd3抗體葉酸生物共軛物及其用途
BR112023003366A2 (pt) 2020-08-25 2023-05-09 Gilead Sciences Inc Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso
CN114853897B (zh) * 2021-04-15 2024-01-26 北京大学深圳研究生院 抗cd19/cd22/cd3三特异性抗体及用途
IL310700A (en) * 2021-08-09 2024-04-01 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies
EP4619028A2 (en) * 2022-11-18 2025-09-24 JN Biosciences LLC Anti-cd3 antibodies
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法
KR20240139569A (ko) * 2023-03-13 2024-09-23 머스트바이오 주식회사 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
MXPA04002621A (es) 2001-09-21 2004-07-08 Univ Tulane Conjugados de analogos de somatostatina o bombesina para diagnostico o terapeuticos y usos de los mismos.
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
WO2005098998A1 (ja) 2004-03-30 2005-10-20 Kureha Corporation 非水電解質二次電池用負極材料、その製造方法、負極および電池
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
ES2616316T3 (es) 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos
WO2007058725A2 (en) 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
ES2547554T3 (es) 2005-11-16 2015-10-07 Ambrx, Inc. Métodos y composiciones que comprenden aminoácidos no naturales
CA2631491C (en) 2005-12-14 2015-02-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US20090240029A1 (en) 2005-12-30 2009-09-24 Ambrx, Inc. Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
JP2009523815A (ja) 2006-01-19 2009-06-25 アンブルックス，インコーポレイテッド 免疫原性が調節された非天然アミノ酸ポリペプチド
KR20090100407A (ko) 2006-12-18 2009-09-23 암브룩스, 인코포레이티드 비천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비천연 아미노산 및 폴리펩티드의 용도
WO2008083346A1 (en) 2006-12-28 2008-07-10 Ambrx, Inc. Phenazine and quinoxaline substituted amino acids and polypeptides
SI2187965T1 (sl) 2007-08-17 2020-03-31 Purdue Research Foundation Office Of Technology Commercialization Konjugati vezalca ligand-veznika PSMA in metode za uporabo
EP2211903A4 (en) 2007-10-17 2011-07-06 Nuvelo Inc CLL-1 ANTIBODY
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
DK2291659T3 (en) 2008-05-13 2015-12-21 Univ Yale SMALL CHEMICAL MOLECULES FOR RECRUITING ANTIBODIES TO CANCER CELLS
CN102224238B (zh) 2008-09-26 2015-06-10 Ambrx公司 非天然氨基酸复制依赖性微生物和疫苗
US20120189621A1 (en) * 2011-01-21 2012-07-26 Yann Dean Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
CA2836857C (en) 2011-05-21 2019-12-03 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
SG10201605293PA (en) 2011-05-27 2016-08-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US9796754B2 (en) 2011-05-27 2017-10-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2014051433A1 (en) 2012-09-27 2014-04-03 Merus B.V. BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
JP6444874B2 (ja) * 2012-10-08 2018-12-26 ロシュ グリクアート アーゲー ２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) * 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
JP2016512421A (ja) 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
EP2970505A4 (en) 2013-03-14 2016-10-19 California Inst Biomedical Res SPECIFIC ANTIBODIES AND USES THEREOF
TW201446804A (zh) 2013-05-14 2014-12-16 Ambrx公司 新穎多肽小分子結合物及其用途
SMT201700559T1 (it) 2013-06-07 2018-01-11 Rhizen Pharmaceuticals S A Doppi iniditori selettivi della pi3 chinasi delta e gamma
JP6637415B2 (ja) * 2013-10-15 2020-01-29 ザ スクリプス リサーチ インスティテュート キメラ抗原受容体ｔ細胞スイッチおよびその使用
US9493563B2 (en) 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
PT3083689T (pt) 2013-12-17 2020-08-27 Genentech Inc Anticorpos anti-cd3 e métodos de utilização
CN113549153A (zh) 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
EP3411069B1 (en) 2016-02-04 2024-07-10 The Scripps Research Institute Humanized anti-cd3 antibodies, conjugates and uses thereof

Also Published As

Publication number Publication date
EP3411069A4 (en) 2020-02-19
EP3411069B1 (en) 2024-07-10
KR20180104157A (ko) 2018-09-19
WO2017136659A3 (en) 2017-09-08
CN109069635A (zh) 2018-12-21
CA3013463A1 (en) 2017-08-10
US20230192844A1 (en) 2023-06-22
KR102891788B1 (ko) 2025-11-26
AU2017213886B2 (en) 2024-03-07
JP2022023052A (ja) 2022-02-07
AU2017213886A1 (en) 2018-08-16
JP2019512002A (ja) 2019-05-09
CN109069635B (zh) 2023-09-26
US12252534B2 (en) 2025-03-18
WO2017136659A2 (en) 2017-08-10
EP3411069A2 (en) 2018-12-12
CA3013463C (en) 2024-05-21
ES2992761T3 (en) 2024-12-17

Similar Documents

Publication Publication Date Title
JP6951826B2 (ja) ヒト化抗ｃｄ３抗体、その複合体、およびその使用
TWI815815B (zh) Bcma單株抗體-藥物結合物
US12377163B2 (en) Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
JP2025060760A (ja) アマトキシン抗体薬物複合体及びその使用
TW201832778A (zh) 對ａｓｃｔ２具有特異性的結合分子及其用途
JP7042876B2 (ja) Ｃｙｓ８０抱合型免疫グロブリン
JP2025508009A (ja) ＦＲαに対する結合分子
WO2021161287A2 (en) Engineered anti-il-2 antibodies
BR112021003843A2 (pt) biconjugados de folato de anticorpo anti-cd3 e seus usos
KR20240141178A (ko) 이중특이적 항원-결합 분자 및 이의 용도
JP7762294B2 (ja) 抗ｃｄ３９抗体ー薬物複合体及びその使用
JP2024544757A (ja) タンパク質複合体の組成物およびその使用方法
WO2021173889A1 (en) Uses of anti-cd3 antibody folate bioconjugates
HK40000405A (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
HK40000405B (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
JPWO2020219778A5 (cg-RX-API-DMAC7.html)
RU2852363C1 (ru) Конъюгат антитела к cd79b и лекарственного средства, способ его получения и его фармацевтическое применение
TWI904109B (zh) 抗ｃｄ４５抗體及其結合物
JP2025088767A (ja) ＰＳＭＡ－ＳＴＥＡＰ１二重可変ドメイン免疫グロブリン（ＤＶＤ－Ｉｇ）分子及び薬物コンジュゲート
JPWO2020219774A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210924

R150 Certificate of patent or registration of utility model

Ref document number: 6951826

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250